03:53 AM EDT, 10/24/2025 (MT Newswires) -- GSK (GSK) said late Thursday the US Food and Drug Administration has approved its Blenrep drug in combination with bortezomib and dexamethasone for the treatment of certain adults with relapsed or refractory multiple myeloma.

The approval was supported by data from a phase 3 trial in which the drug combination showed a 51% reduction in the risk of death, the company said.

Interim efficacy and safety data for Blenrep as a first-line treatment for multiple myeloma, a type of blood cancer, are expected in early 2028, GSK said.